Testosterone Gel (AndroGel): Complete Clinical Guide to TRT Delivery Options

What Is Testosterone Gel and How Does AndroGel Work?

AndroGel is a hydroalcoholic gel delivering testosterone transdermally across the scrotal or body skin into systemic circulation, bypassing first-pass hepatic metabolism entirely. Applied once daily to shoulders, upper arms, or abdomen, it produces stable serum levels without the peaks and troughs typical of weekly injectables. Absorption averages about 10% of the applied dose, meaning a 40.5 mg pump delivers roughly 4 mg of testosterone systemically per day.

The FDA approved AndroGel 1% in 2000 and the more concentrated AndroGel 1.62% formulation in 2011, both indicated for males with primary or hypogonadotropic hypogonadism confirmed by two morning total testosterone measurements below 300 ng/dL [1]. The Endocrine Society defines symptomatic hypogonadism as testosterone consistently below 300 ng/dL combined with at least one classical symptom: reduced libido, fatigue, loss of muscle mass, depressed mood, or decreased bone density [2].

Once absorbed, exogenous testosterone undergoes the same peripheral conversion as endogenous hormone: aromatase converts a fraction to estradiol (E2), and 5-alpha-reductase converts a fraction to dihydrotestosterone (DHT). Both metabolites are biologically active and contribute to clinical outcomes including libido, erythropoiesis, and prostate health. Gel formulations tend to produce proportionally higher DHT elevations than injectables, a pharmacokinetic difference that clinicians weigh when selecting a route [3].

A 182-subject, placebo-controlled trial published in the Journal of Clinical Endocrinology and Metabolism found that AndroGel 1% (100 mg/day) normalized total testosterone in 77% of hypogonadal men at 90 days and significantly improved sexual function scores and lean mass compared with placebo (P<0.001) [4].

AndroGel Dosing Protocol: Starting Dose, Titration, and Monitoring

The AndroGel 1.62% prescribing label recommends starting at 40.5 mg (two pump actuations) applied once every morning. Labs are drawn at day 14 to assess serum testosterone; the dose may be increased to 60.75 mg or 81 mg, or decreased to 20.25 mg, based on that result [1].

Most clinicians target a mid-morning total testosterone of 400 to 700 ng/dL during therapy, checking labs two hours after application to capture the approximate daily peak. The Endocrine Society 2018 guideline recommends against targeting levels above 700 ng/dL in older men or those with cardiovascular risk factors, citing insufficient long-term safety data at supraphysiological exposures [2].

Monitoring schedule after dose stabilization typically follows this cadence:

• 3 months: Total T, free T, hematocrit, PSA, and symptom re-evaluation
• 6 months: Repeat the same panel; add bone mineral density baseline if indicated
• Annually: Full panel including lipids and metabolic markers

Hematocrit above 54% is the threshold at which most guidelines recommend dose reduction or temporary discontinuation to reduce thromboembolic risk [2]. The FDA added a black-box warning in 2015 regarding secondary exposure in children and requires gel manufacturers to include a Medication Guide for patients [5].

Transfer Risk: The Most Underappreciated Safety Issue With Testosterone Gel

Skin-to-skin transfer of testosterone gel to female partners and children is not theoretical. It is documented in regulatory databases and case series. The FDA has received reports of virilization in children whose only confirmed exposure was contact with a treated adult's application site [5].

Practical mitigation steps drawn from the FDA prescribing information [1]:

1. Apply gel to shoulders, upper arms, or abdomen only (not genitals or axilla unless specifically directed by a product label).
2. Allow the site to dry completely before dressing, typically 3 to 5 minutes.
3. Wear a shirt covering the application site whenever skin-to-skin contact with a partner or child is likely.
4. Wash hands with soap and water immediately after application.
5. Shower before intimate skin contact if the gel was applied less than 2 hours earlier.

Partners who notice symptoms such as acne, abnormal hair growth, or clitoral enlargement should seek medical evaluation promptly [5]. Children showing signs of precocious puberty warrant urgent endocrinology referral.

Testosterone Cypionate: The Most Prescribed Injectable in the United States

Testosterone cypionate (TC) is an oil-suspended esterified testosterone with a half-life of approximately 8 days, making weekly or twice-weekly intramuscular or subcutaneous injection practical. TC is the most commonly prescribed injectable TRT formulation in the United States and carries a substantially lower cost than branded gels [6].

A standard clinical starting dose is 100 mg intramuscularly or subcutaneously weekly, with titration based on trough levels drawn immediately before the next injection. Many patients and clinicians prefer twice-weekly dosing at 50 to 75 mg per injection to flatten the peak-to-trough swing, which can otherwise span 300 to 400 ng/dL over 7 days [7].

A pharmacokinetic study (N=12) published in the Journal of Clinical Pharmacology demonstrated that weekly TC at 200 mg produced peak serum testosterone of 1 to 112 ng/dL at 48 hours post-injection, falling to 412 ng/dL by day 7. Splitting the dose to 100 mg twice weekly reduced the peak to 742 ng/dL and the trough to 498 ng/dL, a 63% reduction in intra-week variability [7]. Many men report that energy, mood, and libido track more evenly with twice-weekly dosing for this reason.

TC is dissolved in cottonseed oil and contains benzyl alcohol as a preservative. Men with oil or alcohol sensitivity should disclose this before starting injectable therapy [6].

Testosterone Enanthate: Europe's Standard Injectable and Its U.S. Role

Testosterone enanthate (TE) shares nearly identical pharmacokinetics with cypionate. Its half-life runs approximately 4.5 to 5 days (slightly shorter than TC's 8-day estimate), which in practice changes clinical behavior only marginally. TE is the dominant injectable in Europe, where it is marketed as Testoviron and Delatestryl, and it remains the reference compound in many landmark androgen-deficiency trials [8].

The FDA-approved Delatestryl label lists a dosing range of 50 to 400 mg every 2 to 4 weeks for hypogonadism, though most contemporary TRT clinicians dose 100 to 200 mg weekly or 50 to 100 mg twice weekly to maintain more physiologic levels [9]. TE is carried in sesame oil rather than cottonseed oil, which matters for patients with sesame allergies. Outside of that difference and slight half-life variation, cypionate and enanthate are clinically interchangeable for TRT purposes according to the American Urological Association's 2022 testosterone deficiency guideline [10].

A 12-month open-label study in 160 hypogonadal men treated with TE 250 mg every 3 weeks found that mean total testosterone averaged 461 ng/dL across the dosing interval, with quality-of-life scores (IIEF-5, SF-36) improving significantly from baseline at 6 months (P<0.001) [8]. The every-3-week interval is now considered suboptimal for symptom control; most modern protocols favor weekly or twice-weekly administration.

Testosterone Propionate: Short Half-Life, Specialized Use Cases

Testosterone propionate (TP) carries a half-life of just 0.8 to 1.5 days, requiring injection every 2 to 3 days to maintain stable serum levels. This frequency makes it poorly suited to most standard TRT protocols. Its primary contemporary role is in compounded combination formulations or for patients who need rapid dose adjustments, such as during fine-tuning of polycythemia or erythrocytosis [11].

Some compounding pharmacies combine TP with cypionate or enanthate to provide both a rapid initial rise and a sustained plateau in a single injection. The clinical rationale is plausible, but controlled trial data comparing combination formulations to single-ester injections in a TRT population are limited [11]. Patients should weigh the injection burden (every 2 to 3 days minimum) against the marginal stability benefit before choosing a propionate-containing regimen.

Testosterone Pellets: Longest Duration, Least Flexible

Subcutaneous testosterone pellets (Testopel is the principal FDA-approved brand) consist of fused crystalline testosterone implanted in the gluteal subcutaneous fat under local anesthesia. Each pellet releases testosterone over 3 to 6 months through a slow dissolution process governed by surface area and vascularization [12].

A typical insertion involves 10 to 12 pellets (75 mg each, totaling 750 to 900 mg) placed through a small trocar incision. Serum testosterone peaks around week 4 and declines gradually toward the end of the dosing interval. A retrospective analysis of 1,031 hypogonadal men receiving Testopel found mean total testosterone of 612 ng/dL at 12 weeks post-insertion, dropping to 382 ng/dL at 24 weeks, with 92% of men remaining in the eugonadal range (>300 ng/dL) through week 20 [12].

The main drawbacks are procedural: pellet insertion requires a minor office procedure every 3 to 6 months and carries a 5 to 10% rate of pellet extrusion at the insertion site, particularly when physical activity is resumed too soon post-procedure [13]. Unlike injectables or gel, the dose cannot be adjusted or discontinued immediately if adverse effects emerge. This inflexibility is a real clinical limitation during the initial titration phase of TRT.

Side-by-Side Comparison: Gel vs. Injectables vs. Pellets

The table below summarizes key pharmacokinetic and practical differences across the major TRT formulations. Clinicians and patients should review this alongside individual lab results and lifestyle factors before selecting a route.

| Formulation | Half-Life | Dosing Frequency | DHT Elevation | Transfer Risk | Dose Adjustability | |---|---|---|---|---|---| | AndroGel 1.62% | 24 hours (daily reapplication) | Once daily | Higher than injectables | Yes (skin-to-skin) | Easy (daily titration) | | Testosterone Cypionate | ~8 days | Weekly or twice-weekly | Moderate | None | Moderate | | Testosterone Enanthate | ~4.5 to 5 days | Weekly or twice-weekly | Moderate | None | Moderate | | Testosterone Propionate | 0.8 to 1.5 days | Every 2 to 3 days | Moderate | None | High but burdensome | | Testosterone Pellets (Testopel) | 3 to 6 months | Every 3 to 6 months (procedure) | Moderate | None | Very low |

Gel suits men who prefer to avoid injections and have no household members at risk for transfer. Cypionate or enanthate suits men comfortable with self-injection who value a simple once or twice-weekly protocol. Pellets suit men who want maximum convenience after an initial stable dose is confirmed [2, 10, 12].

Who Should Not Use Testosterone Gel or Any TRT Formulation

The Endocrine Society 2018 guideline lists absolute contraindications that apply to all TRT routes [2]:

• Prostate cancer (known or suspected) or male breast cancer
• Hematocrit above 54% at baseline
• Severe untreated obstructive sleep apnea
• Uncontrolled heart failure
• Desire to preserve fertility in the near term (exogenous testosterone suppresses LH and FSH, impairing spermatogenesis)

Men planning future fertility should consider human chorionic gonadotropin (hCG) monotherapy or clomiphene citrate instead of exogenous testosterone, as these agents stimulate endogenous production rather than suppressing the hypothalamic-pituitary-gonadal (HPG) axis [2, 14].

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found no statistically significant increase in major adverse cardiovascular events (MACE) in men aged 45 to 80 with hypogonadism and high cardiovascular risk treated with testosterone undecanoate oral capsules versus placebo over a median follow-up of 21.7 months, though the trial found a higher rate of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone arm [15]. These findings reinforce the need for individualized risk assessment before initiating any TRT formulation, including gel.

Managing Common Side Effects Across All TRT Routes

Erythrocytosis. All exogenous testosterone formulations stimulate erythropoietin, raising hematocrit. Injectable testosterone produces this effect more consistently than gel because of higher peak levels. The AUA guideline recommends dose reduction or phlebotomy when hematocrit exceeds 54% [10]. Switching from an injectable to gel often brings hematocrit down by 2 to 4 percentage points within 12 weeks.

Estradiol elevation. Aromatization of exogenous testosterone to estradiol causes nipple tenderness, water retention, and mood changes in a minority of men. Serum E2 above 40 to 50 pg/mL with symptoms may warrant low-dose anastrozole (0.25 to 0.5 mg twice weekly), though routine aromatase inhibitor use is not endorsed by the Endocrine Society guideline absent confirmed symptoms and elevated labs [2].

Testicular atrophy and suppressed spermatogenesis. All exogenous androgen suppresses gonadotropins. Men on TRT who wish to preserve testicular size and fertility potential should discuss adjunctive hCG (typically 500 to 1 to 000 IU subcutaneously two to three times per week) with their prescribing clinician [14, 16].

Acne and oily skin. DHT-driven effects on sebaceous glands are more pronounced with gel than with injectables due to higher DHT conversion at the skin level. Switching formulations or lowering the gel dose resolves most cases within 4 to 6 weeks [3].

Sleep apnea worsening. Testosterone can worsen existing obstructive sleep apnea or, in susceptible individuals, precipitate new-onset episodes. A pre-treatment sleep history is standard in guideline-concordant TRT evaluation [2].

How Labs Are Interpreted During TRT: Practical Reference Ranges

Serum testosterone interpretation depends on the formulation and timing of the draw [2, 10]:

• Gel: Draw 2 to 4 hours after application to capture the approximate daily maximum. Target 400 to 700 ng/dL.
• Cypionate or enanthate (weekly dosing): Draw at trough (immediately before the next injection). Target trough >350 ng/dL, peak <1 to 100 ng/dL.
• Cypionate or enanthate (twice-weekly dosing): Draw at trough. Target 400 to 600 ng/dL for most patients.
• Pellets: Draw at weeks 4 and 12 after insertion to assess peak and mid-interval levels.

Free testosterone (free T) becomes the operative metric when sex hormone-binding globulin (SHBG) is abnormally high or low. Men with obesity often have low SHBG, making total T appear misleadingly low; free T corrects for this. The Endocrine Society recommends equilibrium dialysis as the most accurate free T assay method [2].

PSA should be checked at 3 to 6 months after TRT initiation. A rise of more than 1.4 ng/mL above baseline within the first 12 months, or any single PSA above 4.0 ng/mL, warrants urology referral regardless of the TRT formulation used [2, 10].

Testosterone Gel for Specific Populations: Older Men, Obese Men, and Men Post-Hypogonadotropic Hypogonadism Treatment

Older men (over 65) deserve particular attention. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 and older with total testosterone below 275 ng/dL, found that 12 months of testosterone gel 1% improved sexual function, walking distance (6-minute walk test improved by 20 meters vs. 12 meters placebo, P=0.003), and bone mineral density, but did not significantly improve vitality scores compared with placebo [17]. The TTrials also found a higher rate of coronary artery noncalcified plaque volume increase in the testosterone arm, which the authors flagged as a signal requiring further investigation [17].

Obese men often absorb gel poorly because of thicker subcutaneous fat layers over application sites, and they aromatize testosterone more aggressively due to higher peripheral aromatase activity in adipose tissue. For these patients, injectables often produce more predictable serum levels than gel [3, 7].

Men recovering from hypothalamic or pituitary causes of hypogonadism (hypogonadotropic hypogonadism) who want to restore endogenous function should not use exogenous testosterone as first-line therapy. Pulsatile GnRH, gonadotropin therapy, or clomiphene citrate are the approaches that preserve the HPG axis while addressing symptoms [2, 14].

Practical Guidance on Switching Between TRT Formulations

Men switching from injectable testosterone to gel should start gel the day the next injection would have been due, allowing endogenous clearance of the ester. Men switching from gel to injectables can begin the injection on the same day they stop the gel. Pellet removal is not clinically feasible once implanted; the formulation change option only exists at the next insertion appointment [10, 12].

When moving from weekly cypionate to twice-weekly dosing to reduce peak-trough variability, the total weekly dose stays the same, split into two equal halves. Most patients notice smoother energy and mood within 3 to 4 weeks of the split schedule [7].

A man moving from gel to pellets should have at least two stable total testosterone readings in the target range on gel before pellet dosing is calculated, as the pellet dose is estimated from current serum levels and body weight. An undertreated patient receiving pellets sized for a lower target will exit the normal range before the 4-month mark [12].